HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Herpesvirus infection — Clinical Guidelines

Overview

Herpesvirus infections encompass a range of diseases caused by viruses in the Herpesviridae family, including conditions like cold sores, chickenpox, shingles, and more severe complications in immunocompromised individuals. These viruses establish lifelong latency, often reactivating under immunosuppressive conditions. 8

Diagnosis

Key Diagnostic Criteria: Clinical presentation (lesions, symptoms) and history of exposure.

Recommended Tests: Polymerase Chain Reaction (PCR) for rapid identification from lesion swabs. 5

Specific Viruses Tested: HSV-1, HSV-2, VZV; CMV, EBV, HHV-8 tested selectively. 5

Management

First-Line Treatments:

- Acyclovir: Commonly used for HSV and VZV infections. - Valacyclovir: Prodrug of acyclovir, often preferred for its bioavailability. - Ganciclovir: Used primarily for CMV infections, especially in immunocompromised patients. - Foscarnet: Alternative for resistant cases, particularly concerning CMV.

Adverse Effects Monitoring:

- Hematotoxicity: Monitor closely, especially with ganciclovir and foscarnet. 1 - Renal Impairment: Foscarnet and ganciclovir pose higher risks; monitor renal function. 1 - Hepatotoxicity: Ganciclovir associated with acute-on-chronic liver failure; foscarnet with fulminant hepatitis. 1 - Neurotoxicity: Acyclovir and valacyclovir require vigilance for neurological symptoms. 1

Special Populations

Pediatrics: Genital herpesvirus infection can occur in prepubertal children, necessitating careful clinical evaluation. 9

Immunocompromised Individuals: Higher risk of severe infections and reactivation; ganciclovir and foscarnet may be required. 1 5

Renal Impairment: Use acyclovir cautiously due to lower risk compared to other agents; dose adjustments may be necessary. 1

Key Recommendations

Monitor Adverse Events Closely: Regularly assess for hematotoxicity, renal impairment, hepatotoxicity, and neurotoxicity, especially with ganciclovir, foscarnet, and acyclovir use. (Evidence: Moderate 1)

Utilize PCR for Rapid Diagnosis: Employ PCR testing from lesion swabs for timely identification of HSV-1, HSV-2, and VZV infections. (Evidence: Moderate 5)

Consider Patient-Specific Factors: Tailor treatment choices based on patient comorbidities, particularly renal function and immune status. (Evidence: Expert opinion 1 5)

References

1 He D, Kong D, Zeng Y, Han M, Zhang S, Li Z. Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database. Expert opinion on drug safety 2025. link 2 Gao C, Dong X, Zhang J, Mao L, Guo C, Qin X et al.. Recommendations for the selection of nucleoside analogues as antihuman herpesvirus drugs: a real-world analysis of reported cases from the FDA adverse event reporting system. Expert opinion on drug safety 2025. link 3 Rani NA, Robin TB, Prome AA, Ahmed N, Moin AT, Patil RB et al.. Development of multi epitope subunit vaccines against emerging carp viruses Cyprinid herpesvirus 1 and 3 using immunoinformatics approach. Scientific reports 2024. link 4 Cohen J. 'Gene drive' may help fight viruses with viruses. Science (New York, N.Y.) 2023. link 5 Schremser V, Antoniewicz L, Tschachler E, Geusau A. Polymerase chain reaction for the diagnosis of herpesvirus infections in dermatology : Analysis of clinical data. Wiener klinische Wochenschrift 2020. link 6 Lin LY, Bhate K, Forbes H, Smeeth L, Warren-Gash C, Langan S. Vitamin D deficiency or supplementation and the risk of human herpesvirus infections or reactivation: a systematic review protocol. BMJ open 2019. link 7 Drago F, Ciccarese G, Parodi A. Human Herpesvirus-7 Papular Rash: A Comment to Brazzelli et al. Acta dermato-venereologica 2017. link 8 Melnick JL. The herpesvirus group. Bulletin of the Pan American Health Organization 1977. link 9 Hare MJ, Mowla A. Genital herpesvirus infection in a prepubertal girl. British journal of obstetrics and gynaecology 1977. link 10 McCombs RM. Concentration and purification of herpesviruses (simplex, cytomegalo, and EB) in a zonal ultracentrifuge. Applied microbiology 1969. link

Herpesvirus infection